News summary

Annovis wins patent on Alzheimer’s drug through 2044

Source: Longevity Technology • Published: 20 Nov 2026, 18:08

Summarized by Masters of Longevity from Longevity Technology.

A US patent was granted for a new buntanetap crystal form as Phase 3 nears.

Annovis wins patent on Alzheimer’s drug through 2044
Key Takeaways
  • Annovis was granted a buntanetap patent through 2044.
  • The patent was for the crystal form used in Phase 3.
  • Different crystal forms are treated as legally distinct drugs.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.